tetano
Editor, Senior Moderator
Pathog Dis. 2018 Sep 3. doi: 10.1093/femspd/fty070. [Epub ahead of print]
[h=1]Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides lead to dose sparing and protect against lethal challenge in the mouse model.[/h] Sadati SF[SUP]1,[/SUP][SUP]2[/SUP], Jamali A[SUP]3[/SUP], Abdoli A[SUP]4[/SUP], Abedi-Valugerdi M[SUP]5[/SUP], Gholami S[SUP]6[/SUP], Alipour S[SUP]7[/SUP], Soleymani S[SUP]4[/SUP], Kheiri MT[SUP]3[/SUP], Atyabi F[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Lack of efficient delivery systems for transporting antigenic molecules to the cytosol of antigen presenting cells presents a major obstacle for antigen uptake by immune cells. To this end, influenza Whole Inactivated Virus (WIV) vaccines were formulated with chitosan nanoparticles and CpG oligonucleotide as a biodegradable delivery system and a Th1-specific adjuvant, respectively. Intradermal injection of a single high dose and low dose of formulated candidate vaccines was carried out. Thirty days after injection; cell proliferation assay (MTT), IFN-gamma and IL-4 ELISpot assays were carried out. Sera samples were collected 21days after immunization to measure IgG1 and IgG2a levels. In addition, the mice challenged with mouse adopted virus, were monitored for weight loss. The results show a significant stimulation of both humoral and cellular immunities; also weight gain and a decrease in mortality in the mice receiving both dosages of inactivated influenza virus vaccines with CpG and Chitosan coating were observed. Based on our results, it can be concluded that formulation of inactivated Influenza virus with CpG and its delivery by Chitosan as low-dose in return of high-dose with the same results as balanced between cellular and humeral immune responses can make enormous saving in manufacturing vaccine.
PMID: 30184220 DOI: 10.1093/femspd/fty070
[h=1]Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides lead to dose sparing and protect against lethal challenge in the mouse model.[/h] Sadati SF[SUP]1,[/SUP][SUP]2[/SUP], Jamali A[SUP]3[/SUP], Abdoli A[SUP]4[/SUP], Abedi-Valugerdi M[SUP]5[/SUP], Gholami S[SUP]6[/SUP], Alipour S[SUP]7[/SUP], Soleymani S[SUP]4[/SUP], Kheiri MT[SUP]3[/SUP], Atyabi F[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Lack of efficient delivery systems for transporting antigenic molecules to the cytosol of antigen presenting cells presents a major obstacle for antigen uptake by immune cells. To this end, influenza Whole Inactivated Virus (WIV) vaccines were formulated with chitosan nanoparticles and CpG oligonucleotide as a biodegradable delivery system and a Th1-specific adjuvant, respectively. Intradermal injection of a single high dose and low dose of formulated candidate vaccines was carried out. Thirty days after injection; cell proliferation assay (MTT), IFN-gamma and IL-4 ELISpot assays were carried out. Sera samples were collected 21days after immunization to measure IgG1 and IgG2a levels. In addition, the mice challenged with mouse adopted virus, were monitored for weight loss. The results show a significant stimulation of both humoral and cellular immunities; also weight gain and a decrease in mortality in the mice receiving both dosages of inactivated influenza virus vaccines with CpG and Chitosan coating were observed. Based on our results, it can be concluded that formulation of inactivated Influenza virus with CpG and its delivery by Chitosan as low-dose in return of high-dose with the same results as balanced between cellular and humeral immune responses can make enormous saving in manufacturing vaccine.
PMID: 30184220 DOI: 10.1093/femspd/fty070